Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Update

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a significant increase in short interest in February. As of February 15th, there was short interest totalling 21,000 shares, an increase of 65.4% from the January 31st total of 12,700 shares. Based on an average daily volume of 74,300 shares, the short-interest ratio is presently 0.3 days.

Global X Genomics & Biotechnology ETF Stock Up 0.8 %

Shares of NASDAQ GNOM traded up $0.07 during trading on Friday, reaching $9.23. 74,832 shares of the stock were exchanged, compared to its average volume of 67,870. The business’s 50-day moving average price is $9.88 and its 200 day moving average price is $10.49. Global X Genomics & Biotechnology ETF has a twelve month low of $9.04 and a twelve month high of $12.53. The company has a market capitalization of $64.33 million, a price-to-earnings ratio of -3.94 and a beta of 1.03.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in GNOM. Raymond James Financial Inc. acquired a new position in shares of Global X Genomics & Biotechnology ETF during the fourth quarter worth $2,974,000. Flow Traders U.S. LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF during the third quarter worth $936,000. Armis Advisers LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF during the fourth quarter worth $432,000. Strive Asset Management LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF during the fourth quarter worth $409,000. Finally, Two Sigma Investments LP lifted its position in shares of Global X Genomics & Biotechnology ETF by 74.5% during the fourth quarter. Two Sigma Investments LP now owns 85,500 shares of the company’s stock worth $830,000 after purchasing an additional 36,500 shares in the last quarter. 56.95% of the stock is owned by institutional investors and hedge funds.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.